NCT00463723终止2 期
Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
University Hospital Freiburg0 个研究点开始时间: 2007年4月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
研究概览
简要总结
Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a wide range of side effects. The efficacy of topial FK506 in preventing immune reactions has already been demonstrated experimentally. FK506, an IL-2-inhibitor like Cyclosporin A (CSA), is known to be approximately 100 fold more potent than CSA. Aim of the study: In this study the efficacy and safety of topical FK506 will be compared to our standard treatment (i.e. steroids) after penetrating normal-risk keratoplasty.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Penetrating keratoplasty for Keratoconus
- •Penetrating keratoplasty for Fuchs endothelial dystrophie
- •Penetrating keratoplasty for Bullous keratopathy
排除标准
- •Limbal stem cell deficiency
- •Herpetic eye disease
- •Repeat Keratoplasty
研究者
相似试验
进行中（未招募）
1 期
Topical rVA576 for treatment of atopic keratoconjunctivitis: a randomised placebo double masked parallel trial (TRACKER)Moderate to severe atopic keratoconjunctivitis (AKC),Vernal keratoconjunctivitis (VKC),Severe allergic conjunctivitis (seasonal (SAC) or perennial (PAC))MedDRA version: 20.0Level: PTClassification code 10069664Term: Atopic keratoconjunctivitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 21.0Level: PTClassification code 10081000Term: Vernal keratoconjunctivitisSystem Organ Class: 10015919 - Eye disordersMedDRA version: 21.0Level: LLTClassification code 10081002Term: Vernal keratoconjunctivitis perennialSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.0Level: LLTClassification code 10001709Term: Allergic conjunctivitisSystem Organ Class: 10015919 - Eye disordersEUCTR2017-002835-40-ESAkari Therapeutics Plc19
已完成
2 期
Prospective, Randomized Trial of Basiliximab (Simulect) in the Prophylaxis of High-Risk Keratoplasty PatientsCorneal TransplantationNCT00409656University Hospital Freiburg
撤回
不适用
Topical Steroid Treatment After Posterior Lamellar Corneal TransplantationEndothelial DystrophySecondary Bullous KeratopathyPosterior Lamellar KeratoplastyDescemet's Stripping Endothelial KeratoplastyNCT01682421Aarhus University Hospital
招募中
2 期
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted AngiomaTacrolimus, Kaposiform Hemangioendothelioma, Tufted AngiomaNCT04056962West China Hospital50
撤回
1 期
Topical Infliximab in Autoimmune Eyes With KeratoprosthesisStevens-Johnson SyndromeToxic Epidermal Necrolysis (Lyell) SyndromeMucous Membrane PemphigoidNCT02126020James Chodosh, MD, MPH